<DOC>
	<DOCNO>NCT01904773</DOCNO>
	<brief_summary>This two-part , randomize , multi-center , blind study adolescent Tourette 's Disorder . There 21-day screening period subject eligibility determine . In Part 1 study , safety , tolerability pharmacokinetics AZD5213 assess 1- week period . In Part 2 study , safety , tolerability , preliminary efficacy two dos ( depend tolerability Part 1 study ) AZD5213 placebo assess six consecutive four-week crossover period . Each subject receive AZD5213 placebo . A follow-up vist take place 14 ( ± ) 7 day follow last dose study drug .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetic , Efficacy Study AZD5213 Adolescents With Tourette 's Disorder</brief_title>
	<detailed_description>This multicenter , randomize , two-part study AZD5213 adolescent ( age 12-17 year ) Tourette 's Disorder . In Part 1 study , follow 21-day screening period , Day 1 , baseline procedure perform , eligible subject receive single , low dose AZD5213 , in-clinic . After study drug dose Day 1 , safety tolerability assess in-clinic , blood sample take pharmacokinetic ( PK ) analysis . On Days 2 , 3 , 4 , 5 , 6 7 subject take study drug , contact via telephone adverse event concomitant medication assess . On Day 8 , safety , tolerability , blood sample PK analysis ( predose 2-4 hour post-dose ) perform in-clinic . Part 2 study consist six consecutive crossover period . In Part 2 study , study drug administer two 4-week period ( six treatment period , total ) . Each study drug receive one Periods 1-3 , one Periods 4-6 . Approximately 24 subject receive study drug Part 1 study order complete approximately 18 subject Part 2 .</detailed_description>
	<mesh_term>Tourette Syndrome</mesh_term>
	<criteria>1 . Male female , age ≥ 12 &lt; 18 year baseline ( Day 1 ) . 2 . Meets Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) criteria Tourette 's Disorder , assess KiddieSADS ( Schedule Affective Disorders Schizophrenia ) Present Lifetime Version ( KSADSPL ) Tic Disorder Supplement clinical interview . 3 . Yale Global Tic Severity Scale ( YGTSS ) Total Tic Severity Score ( TTS ) ≥ 20 Screen baseline ( Day 1 ) . 4 . Symptoms Tourette 's Disorder must impair school , occupational , and/or social function . 5 . Written inform assent consent provide subject , write informed consent provide parent ( ) /guardians ( ) , appropriate per Institutional Review Board/Ethics Committee . 6 . Weight ≥ 40 kg screen baseline ( Day 1 ) visit . 7 . In opinion investigator , subject designate guardian ( ) and/or parent ( ) must consider likely comply study protocol high probability complete study . Subjects enter study follow exclusion criterion fulfil : 1 . Prior participation AZD5213 study . 2 . Acute suicidality evidence answer `` yes '' question # 4 question # 5 ColumbiaSuicide Severity Rating Scale ( CSSRS ) , indicate active suicidal ideation intent act , Screen baseline ( Day 1 ) . 3 . Pregnant breastfeeding female . 4 . History seizure disorder single childhood febrile seizure . 5 . Presence psychiatric neurologic disorder symptom , , judgment investigator , psychiatric neurologic disorder symptom likely confound interpretation drug effect affect subject 's ability complete study . 6 . Any clinically important abnormality determine investigator Screen baseline ( Day 1 ) physical neurologic examination , vital sign , ECG , clinical laboratory test result could detrimental subject could affect subject 's ability complete study . 7 . History presence clinically important medical condition , judgement investigator , likely deteriorate , could detrimental subject , could affect subject 's ability complete study . 8 . History presence clinically important sleep disorder .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Combined Multiple Motor Vocal Tic Disorder ; Tourette Disorder ; Gilles de la Tourette Syndrome ; Tourette Disease</keyword>
</DOC>